Assembly Biosciences Inc (ASMB)

• $14.77

  $15.30

  $15.10
  

  2.18%

  Downside

  Day's Volatility :3.46%

  Upside

  1.31%

  
• $7.69

  $20.04

  $15.10
  

  49.07%

  Downside

  52 Weeks Volatility :61.63%

  Upside

  24.65%

  

Returns

What analysts predicted

Upside of 138.41%

• Vanguard Group Inc

  3.58%

• Millennium Management LLC

  2.28%

• Federated Hermes Inc

  0.46%

• Bridgeway Capital Management, LLC

  0.26%

• Marquette Asset Management Inc.

  0.16%

• Acadian Asset Management LLC

  0.11%

assembly biosciences, inc. (nasdaq: asmb) is a public clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis b virus (hbv) infection and novel oral live biotherapeutics for disorders associated with the microbiome. assembly is developing two innovative platform programs: an hbv program advancing a new class of oral therapeutics for the treatment of hepatitis b virus (hbv) infection and a microbiome program developing novel oral live biotherapeutics designed to address diseases associated with the microbiome. assembly’s hbv program is advancing multiple drug candidates with the aim of increasing cure rates in patients with chronic hbv. the company's microbiome program consists of a fully integrated platform that includes a robust strain identification and selection process, methods for strain isolation and growth under current good manufacturing practices and a patent-pending delivery system, gemicel®, which allows for targeted ora